The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
New Uses for New and Old Quinolones and the Challenge of Resistance
Abstract
More than a decade ago ciprofloxacin, the first quinolone with broad indications, was released for clinical use in the United States. The release of ofloxacin, which also had broad applications, followed not long thereafter. Since that time there has been extensive use of these 2 agents and more limited use of other quinolones, such as norfloxacin, enoxacin, and lome-floxacin, which were limited to treatment of infections of the genitourinary tract. Applications of these quinolones largely employed their potent activities against gram-negative bacteria [1, 2]. This article focuses on information developed in the past 4 years on the 4 most recently released quinolones—levofloxacin, sparfloxacin, grepafloxacin, and trovafloxacin [3–8]—and their spectrum of activity, pharmacokinetics, tolerability, and clinical applications. It also focuses on new applications of the older quinolones. Issues of quinolone resistance related to expanding uses of quinolones will also be discussed. The newer fluoroquinolones have retained much of the activity of ciprofloxacin and ofloxacin against enteric gram-negative bacteria, but none is more potent than ciprofloxacin against these pathogens or against Pseudomonas aeruginosa. Levofloxacin is the active stereoisomer of the racemic mixture of the 2 stereoisomers that make up ofloxacin and thus is generally 2-fold more potent than ofloxacin [3]. Trovafloxacin [9] and, to a lesser extent, levofloxacin generally have gram-negative coverage similar to that of ciprofloxacin, but both may be less active against some strains of P. aeruginosa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quinolone-Resistant Campylobacter jejuni Infections in Minnesota, 1992–1998
Smith, K. E., Besser, J. M., Hedberg, C. W., Leano, F. T., Bender, J. B., Wicklund, J. H., Johnson, B. P., Moore, K. A., & Osterholm, M. T. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905203402001 · Cited by 666
Cited by
Emerging Mechanisms of Fluoroquinolone Resistance
Hooper, D. C. (2001) · Emerging Infectious Diseases · doi:10.3201/eid0702.010239 · Cited by 633
Self-citationFluoroquinolones, tuberculosis, and resistance
Ginsburg, A. S., Grosset, J. H., & Bishai, W. R. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00671-6 · Cited by 403
Application of fluoroquinolone pharmacodynamics
Wright, D. H. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.5.669 · Cited by 342
Fluoroquinolone resistance among Gram-positive cocci
Hooper, D. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00369-9 · Cited by 320
Self-citationFluoroquinolones: Action and Resistance
Drlica, K., & Malik, M. (2003) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026033452537 · Cited by 317
Metadata
- Authors
- Hooper, D. C.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-02-01
- Volume
- 30
- Issue
- 2
- Pages
- 243-254
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2139490393
- Cited by
- 171
- References
- 1
- FWCI
- 10.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New Uses for New and Old Quinolones and the Challenge of Resistance. https://app.cochat.ai/papers/10.1086/313677
- The paper
- Hooper, D. C. (2000). New Uses for New and Old Quinolones and the Challenge of Resistance. Clinical Infectious Diseases. https://doi.org/10.1086/313677
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.